Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (отвара нови прозор)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Извор‎: Br J Haematol 2013;161(5):738-40.

Индекс‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (отвара нови прозор)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (отвара нови прозор)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Извор‎: Haematologica 2021;106(4):1148-57.

Индекс‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (отвара нови прозор)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (отвара нови прозор)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Извор‎: Cancer 2008;113(6):1338-43.

Индекс‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (отвара нови прозор)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (отвара нови прозор)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Извор‎: Transfusion 2012;52(4):739-41.

Индекс‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (отвара нови прозор)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (отвара нови прозор)

Bhatia M, Davenport V, Cairo MS.

Извор‎: Leuk Lymphoma 2007;48(1):9-15.

Индекс‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (отвара нови прозор)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (отвара нови прозор)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Извор‎: BMC Cancer 2013;13:121.

Индекс‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (отвара нови прозор)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (отвара нови прозор)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Извор‎: Pathol Oncol Res 2011;17(1):141-3.

Индекс‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (отвара нови прозор)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (отвара нови прозор)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Извор‎: J Neurooncol 2012;106(2):427-9.

Индекс‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (отвара нови прозор)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (отвара нови прозор)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Извор‎: Lancet 2003;361(9354):275-80.

Индекс‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (отвара нови прозор)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (отвара нови прозор)

Ford PA, Grant SJ, Mick R, Keck G.

Извор‎: J Clin Oncol 2015;33(15):1674-9.

Индекс‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (отвара нови прозор)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (отвара нови прозор)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Извор‎: Platelets. 2022 3;33(7):1024-1030.

Индекс‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (отвара нови прозор)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (отвара нови прозор)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Извор‎: Cancer 2014;120(12):1838-46.

Индекс‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (отвара нови прозор)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (отвара нови прозор)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Извор‎: Leuk Lymphoma 2013;54(2):321-8.

Индекс‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (отвара нови прозор)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (отвара нови прозор)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Извор‎: Platelets 2012;23(6):423-9.

Индекс‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (отвара нови прозор)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (отвара нови прозор)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Извор‎: Ann Hematol 2015;94(1):117-28.

Индекс‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (отвара нови прозор)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (отвара нови прозор)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Извор‎: J Hematol Oncol 2015;8:37.

Индекс‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (отвара нови прозор)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (отвара нови прозор)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Извор‎: J Clin Oncol 2010;28(3):437-44.

Индекс‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (отвара нови прозор)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (отвара нови прозор)

Locantore-Ford P, Grant SJ, Keck G.

Извор‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (отвара нови прозор)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (отвара нови прозор)

Loo M, Beguin Y.

Извор‎: Blood 1999;93(10):3286-93.

Индекс‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (отвара нови прозор)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (отвара нови прозор)

Miao J, Leblebjian H, Scullion B, Parnes A

Извор‎: Am J Hematol 2018;93(4):E86-E88.

Индекс‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (отвара нови прозор)

Pharmacological therapies to minimise platelet transfusion. (отвара нови прозор)

Norfolk DR, Seghatchian J.

Извор‎: Transfus Sci 2000;22(3):149-53.

Индекс‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (отвара нови прозор)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (отвара нови прозор)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Извор‎: Support Care Cancer 2014;22(5):1217-22.

Индекс‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (отвара нови прозор)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (отвара нови прозор)

Pathak S, Roth M, Verma A, Steidl U.

Извор‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Индекс‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (отвара нови прозор)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (отвара нови прозор)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Извор‎: Leuk Lymphoma. 2019;60(9):2324-7.

Индекс‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (отвара нови прозор)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (отвара нови прозор)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Извор‎: Lancet Haematol 2015;2(10):e417-26.

Индекс‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (отвара нови прозор)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (отвара нови прозор)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Извор‎: Am J Blood Res 2013;3(3):260-4.

Индекс‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (отвара нови прозор)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (отвара нови прозор)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Извор‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Индекс‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (отвара нови прозор)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (отвара нови прозор)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Извор‎: Blood 2010;116(12):2127-33.

Индекс‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (отвара нови прозор)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (отвара нови прозор)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Извор‎: Blood 2012;120(2):386-94.

Индекс‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (отвара нови прозор)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (отвара нови прозор)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Извор‎: Cancer 2011;117(5):992-1000.

Индекс‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (отвара нови прозор)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (отвара нови прозор)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Извор‎: J Clin Oncol 2019;37(31):2892-8.

Индекс‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (отвара нови прозор)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (отвара нови прозор)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Извор‎: Blood 2000;95(9):2983-9.

Индекс‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (отвара нови прозор)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (отвара нови прозор)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Извор‎: Eur J Haematol 2014;93(5):439-45.

Индекс‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (отвара нови прозор)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (отвара нови прозор)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Извор‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Индекс‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (отвара нови прозор)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (отвара нови прозор)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Извор‎: Ann Oncol 2005;16(1):139-45.

Индекс‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (отвара нови прозор)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (отвара нови прозор)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Извор‎: J Hematol Oncol 2012;5:71.

Индекс‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (отвара нови прозор)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (отвара нови прозор)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Извор‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Индекс‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (отвара нови прозор)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (отвара нови прозор)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Извор‎: Blood 2009;114(18):3899-908.

Индекс‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (отвара нови прозор)